Back to Search
SAUL RIVKIN, MD
MD
Hematology (Internal Medicine) Physician
NPI: 1255415972Individual
Specialties, Licenses & Credentials
Hematology (Internal Medicine) PhysicianPrimary
Internal Medicine — Hematology
Code: 207RH0000X
MD00009378(WA)
Research & Publications (20)
Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.
PMID 18931340·Blood·2009
3-trial
Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.
PMID 19464730·Gynecol Oncol·2009
3-trial
External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial.
PMID 18521920·Cancer·2008
3-trial
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
PMID 18404692·Cancer·2008
8-other
Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial.
PMID 18093738·Pain·2008
4-observational
A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149).
PMID 18175205·J Neurooncol·2008
3-trial
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
PMID 17557954·J Clin Oncol·2007
3-trial
A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.
PMID 16699973·Invest New Drugs·2006
3-trial
Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.
PMID 16683076·Invest New Drugs·2006
3-trial
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.
PMID 17163265·Clin Drug Investig·2006
3-trial
Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.
PMID 15860488·Ann Oncol·2005
3-trial
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
PMID 16293862·J Clin Oncol·2005
4-observational
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.
PMID 15793221·Oncologist·2005
3-trial
Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
PMID 15774775·J Clin Oncol·2005
3-trial
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
PMID 15542803·J Clin Oncol·2004
3-trial
Determinants of gating polarity of a connexin 32 hemichannel.
PMID 15298899·Biophys J·2004
4-observational
Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.
PMID 15337799·J Clin Oncol·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1221 MADISON ST, FIRST FLOOR
SEATTLE, WA 98104 - Phone
- (206) 386-2323
Quick Facts
- NPI
- 1255415972
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile